Halozyme Therapeutics, Inc. (HALO) Down 14.8% — Is It Time to Rotate Out?
Halozyme Therapeutics, Inc. (HALO) is under heavy pressure this Friday, last trading at $104.75 on the NASDAQ. That is an $18.21 drop from the prior close of $122.96 and one of the sharpest single-session declines the stock has posted in recent months. The selloff comes just one week after HALO set a 52-week high of $134.00 on October 30, 2026. Shares now sit roughly 21.8% below that level, and about a week's worth of gains built on months of momentum has been erased in a single morning.
Volume is running well above normal, with roughly 3.14 million shares traded so far against a 90-day average of about 2.16 million. That puts turnover about 46% above its typical pace with the session still open, which points to a broad exit rather than a handful of large trades.
Why Halozyme Therapeutics, Inc. Price is Moving Lower
Today's decline looks like a classic sell-the-news reaction, made worse by an analyst downgrade. It does not reflect any weakness in the quarter itself. Halozyme reported Q3 results on November 5, posting adjusted EPS of $2.39 against a $2.28 consensus and revenue of $493 million versus the $487.13 million expected. Revenue rose 39% year over year, adjusted EPS climbed 42%, and net income increased 41% to $247 million. Royalties reached a record $341 million, up 44%, which confirms that partner products built on Halozyme's delivery technology are still gaining traction.
The problem was the outlook. Management raised its 2026 guidance, but it lifted the revenue midpoint by only $20 million and the adjusted EPS midpoint by just $0.08. That is a modest increase after a quarter that beat on both lines. Expectations were also stretched going into the print. Shares had gained 44.8% since the August report and stood just 2.7% below the $134 high, so a strong quarter needed a bigger guidance raise to justify where the stock was trading. A forward P/E of 38.95 left little room for an incremental update.
Leerink added to the pressure on November 6, cutting HALO from Outperform to Market Perform. Analyst David Risinger pointed to the small third-quarter beat, the limited improvement in the outlook, the stock's prior run, and uncertainty about future growth, including potential royalties tied to Merck's (MRK) injectable Keytruda. Leerink still raised its price target from $110 to $117, which sits above today's trading level. That suggests the downgrade is mainly about valuation rather than a broken thesis. The selling is specific to Halozyme. Larger Health Care names are holding up well, with AbbVie Inc. (ABBV) up 0.52% and Thermo Fisher Scientific Inc. (TMO) up 2.47% on the session.
What is the Halozyme Therapeutics, Inc. Rating - Should I Sell?
Weiss Ratings assigns HALO a B rating. Current recommendation is Buy. Even after today's drop, the rating reflects a business whose fundamentals remain unusually strong. The selloff is a debate about valuation and the pace of future growth, and it does not signal deterioration in the underlying operations.
Halozyme is rated Excellent on four of its five sub-indices. The Excellent Growth Index rating rests on 47.67% revenue growth, an exceptional pace for a company of this size. It is also durable, because it comes from royalties on partner drugs that are already commercialized rather than from one-time milestones. The Excellent Efficiency Index rating reflects the same royalty-driven economics. A 24.85% profit margin and a 173.67% ROE show how much earnings Halozyme generates from a lean capital base when partners such as Roche and Johnson & Johnson carry the cost of developing and selling the drugs. The Excellent Solvency Index rating fits that picture, since a business throwing off quarterly net income of $247 million has ample capacity to meet its obligations. The Total Return Index is also rated Excellent, reflecting a stock that climbed to $134.00 just days ago and rewarded holders well over the measurement period.
The picture becomes more nuanced on the Volatility Index, which is rated Fair. Today's 14.81% drop shows why. A stock that ran nearly 45% in roughly three months can give back a large share of those gains in a single session once the guidance raise falls short and an analyst steps to the sidelines. Investors buying at these levels should expect that kind of swing to remain part of owning HALO, especially while the stock trades near 39 times forward earnings.
Within the Health Care sector, Halozyme sits alongside Eli Lilly and Company (LLY, B) and AbbVie Inc. (ABBV, B). It ranks ahead of Johnson & Johnson (JNJ, B-) and Thermo Fisher Scientific Inc. (TMO, B-), but trails Amgen Inc. (AMGN, B+), which carries a slightly stronger risk/reward profile in Weiss's framework.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) is a Health Care company headquartered in San Diego, California. Its core asset is the ENHANZE drug delivery technology, built on a proprietary recombinant human hyaluronidase enzyme known as rHuPH20. The enzyme temporarily breaks down hyaluronan in the tissue beneath the skin. This allows large-volume biologics that would normally require lengthy intravenous infusions to be given as subcutaneous injections in minutes.
Halozyme licenses ENHANZE to major pharmaceutical partners and collects milestone payments and royalties on the resulting products. Partnered therapies include Roche's Phesgo and Tecentriq Hybreza, Johnson & Johnson's Darzalex Faspro, Bristol Myers Squibb's Opdivo Qvantig, Takeda's HyQvia, and argenx's Vyvgart Hytrulo. Halozyme also sells its own products, including Hylenex recombinant. Through its acquisition of Antares Pharma, it gained auto-injector device capabilities and specialty products such as Xyosted.
Halozyme's competitive advantage comes from its intellectual property estate, its long record of regulatory approvals across partnered products, and the economics of a royalty model that requires little capital from Halozyme once a partner drug reaches market. The shift from intravenous to subcutaneous delivery appeals to patients, physicians, and drug makers looking to extend franchises and reduce infusion-center burden. That gives Halozyme a structural tailwind. Its growth still depends on partners continuing to adopt ENHANZE, and competing subcutaneous delivery approaches remain a key variable for the company's long-term royalty base.
Investor Outlook
Halozyme Therapeutics, Inc. (HALO) carries a Weiss Rating of B (Buy), and today's selloff reflects stretched expectations more than any crack in a quarter that showed 39% revenue growth and record royalties. Investors should watch whether the modest guidance raise proves conservative in Q4, how royalty growth holds up across major partnered products, and whether clarity emerges on the Merck Keytruda question that Leerink flagged. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--